CON Concentra Group Holdings Parent, Inc. Common Stock

CON vs. MEDP: Which Stock Is the Better Value Option?

Here is how Anika Therapeutics (ANIK) and Concentra Group (CON) have performed compared to their sector so far this year.

Concentra Group Holdings Parent (CON) has drawn fresh attention after reporting another earnings beat in August 2026 and opening a new occupational health center in Daytona Beach, Florida, expanding its footprint in a regional hub. Those moves have landed against a strong run in the share price, with Concentra Group Holdings Parent now at US$36.37 and showing an 87.38% year to date share price return. The 1-year total shareholder return of 76.79% points to momentum that has been building...

Concentra (CON) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

CON vs. MEDP: Which Stock Is the Better Value Option?

Does Concentra Group (CON) have what it takes to be a top stock pick for momentum investors? Let's find out.

Here is how CareDx (CDNA) and Concentra Group (CON) have performed compared to their sector so far this year.

Broker rating upgrades spotlight Concentra, QuinStreet and Arrow Electronics, with earnings growth forecasts ranging from 16.8% to 92.7%.

Concentra Group, QuinStreet and Arrow Electronics pair broker rating upgrades with strong projected earnings growth, making them stocks to consider.

CON vs. MEDP: Which Stock Is the Better Value Option?

Does Concentra Group (CON) have what it takes to be a top stock pick for momentum investors? Let's find out.

Patient visits climbed as rate increases drove margin expansion.

Concentra Group Holdings Parent (CON) has given investors a cluster of fresh information in August 2026, including second quarter earnings, new full year guidance, a dividend declaration, leadership changes, and updated buyback activity. See our latest analysis for Concentra Group Holdings Parent. Concentra Group Holdings Parent’s recent earnings beat, raised full year guidance, upcoming conference appearances and planned CEO transition have come against a backdrop of strong share price...

Concentra Group Holdings Parent, Inc. recently reported past second-quarter 2026 results showing sales of US$606.03 million and net income of US$65.3 million, alongside raising its full-year 2026 revenue and earnings guidance and affirming a quarterly cash dividend of US$0.0625 per share. At the same time, the company outlined a multiyear leadership succession in which current president and chief financial officer Matt DiCanio is set to become chief executive officer in November 2026, while...

Concentra Group (CON) is positioned to benefit from a potential pickup in manufacturing and construc

CON vs. MEDP: Which Stock Is the Better Value Option?

Concentra (CON) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Concentra Group Holdings Parent (NYSE:CON) reported higher second-quarter revenue, earnings and cash flow, while also announcing that Chief Executive Officer Keith Newton will transition to Executive Chairman on Nov. 1 and President and Chief Financial Officer Matt DiCanio will become President and

Concentra Group Holdings Parent Inc (CON) reports 10% revenue growth and 22.5% adjusted EBITDA increase, prompting upward revision of full-year 2026 outlook.

Moby summary of Concentra Group Holdings Parent, Inc.'s Q2 2026 earnings call

Concentra (CON) delivered earnings and revenue surprises of +23.81% and +2.28%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Concentra (CON) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Here is how Concentra Group (CON) and Cytokinetics (CYTK) have performed compared to their sector so far this year.

CON vs. MEDP: Which Stock Is the Better Value Option?